Ofri Mizrahi*, Tal FalickMichaeli*, Ayala Hubert, Marc Wygoda, Philip Blumenfeld
Hadassah Medical Center, Department of Radiation Oncology, SharettOncology Center
BACKGROUND
- Pancreatic cancer, particularly in its locally advanced and oligometastaticforms, poses a therapeutic challenge.
- Radiotherapy remains an important treatment in an attempt to gain local control. Data is limited to support specific RT recommendations for locally advanced disease.
- There is no consensus on whether stereotactic body radiotherapy (SBRT) is appropriate as compared to conventionally fractionated radiotherapy (CFRT).
METHODS
We conducted a retrospective analysis for 49 patients with advanced pancreatic cancer, that were treated between 2010 and 2023.
The patients examined received definitive radiotherapy with SBRT 30-50 Gyin 3-5 fractions or CFRT 50-60 Gyin 25-30 fractions.
We excluded all patients with resectable disease who underwent surgery.
Clinicopathological data, treatment regimens and radiation parameters were collected and analyzed. Outcomes include Local Recurrence Free Survival (LRFS), overall survival (OS), Progression Free Survival (PFS) and treatment-related toxicity(graded by CTCAE version 5.0)
Conclusions
In this retrospective study we found no difference in terms of oncologic outcomes or toxicity in patients receiving SBRT in comparison to CFRT for locally advanced and select oligometastaticpancreatic cancers.
Considering the efficiency of SBRT, delivered in fewer treatments and deemed more convenient for patients, our findings suggest that SBRT may emerge as the preferred strategy in select cases.
Further improvement in RT approaches is warranted in order to attempt to improve local control and outcomes in these challenging cases.
Read the full findings >> here
*equal contribution
